What is AVBP's current stock price?

AVBP (ArriVent BioPharma, Inc. Common Stock) is currently trading at $27.65 with a market cap of $1.29B.

What sector is ArriVent BioPharma, Inc. Common Stock in?

ArriVent BioPharma, Inc. Common Stock (AVBP) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AVBP a good stock to buy?

Analysts have a Buy consensus on AVBP with a price target of $45.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AVBP ArriVent BioPharma, Inc. Common Stock

Healthcare

$27.65+0.00%OpenMarket Cap: $1.29B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.72

P/S

0.00

EV/EBITDA

-7.82

DCF Value

$1.05

FCF Yield

-10.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-49.0%

ROA

-41.6%

ROIC

-48.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-43.3M	$—
Q4 null	$0.00	$-35.5M	$—
FY null	$0.00	$-166.3M	$—
Q3 null	$0.00	$-35.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$45.00

Target (Median)

$45.00

Target Range

$45.00 - $45.00

0 Strong Buy12 Buy0 Hold0 Sell0 Strong Sell

CitigroupBuy

2026-05-13

B. Riley SecuritiesBuy

2026-03-23

CitigroupBuy

2026-03-06

OppenheimerOutperform

2026-03-06

HC Wainwright & Co.Buy

2026-03-06

Trading Activity

Insider Trades

View All

Yao Zhengbindirector, officer: President and CEO

SellWed Feb 04

Lutzker Stuartdirector, officer: President of R&D

SellWed Feb 04

LaChapelle Robinofficer: Chief Operating Officer

SellWed Feb 04

Kung Winstonofficer: Chief Financial Officer

SellWed Feb 04

Kastenmayer James Paulofficer: General Counsel

SellWed Feb 04

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.52

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Peers

DNA

MBX